A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving rituximab,chidamide, and zanubrutinib with
Sequential chemotherapy works in treating patients with double express diffuse large B-cell
lymphoma. The prognosis of patients with DEL-DLBCL is usually worse than that of ordinary
DLBCL.